Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies in Drug Discovery

Serge Muyldermans's Biography

Serge Muyldermans, Professor, Vrije Universiteit

Serge Muyldermans obtained his PhD at the ‘Vrije Universiteit Brussel’, Brussels, Belgium in 1982. He was postdoc at this university at the time the functional Heavy-chain only antibodies were discovered in camelids and developed a streamlined method to identify antigen-specific, single-domain antibody fragments derived from these unique Heavy chain antibodies. This technology was used to found Ablynx NV in December 2001, a Belgian private biotech company actively developing protein therapeutics based on single variable domains or NanobodiesTM and currently employing 300 people. In 2003, he became professor at the ‘Vrije Universiteit Brussel’ where he is heading the camel-antibody engineering group in the laboratory for Cellular and Molecular Immunology.

Serge Muyldermans Image

Pros and Cons of Nanobodies for Drug Discovery

Tuesday, 7 March 2017 at 09:00

Add to Calendar ▼2017-03-07 09:00:002017-03-07 10:00:00Europe/LondonPros and Cons of Nanobodies for Drug

Nanobodies, the antigen binding fragments from heavy chain only antibodies of camelids offer a unique source of minimal-sized potent drugs with multiple beneficial properties and a myriad of possible applications. Llama and camels have unique antibodies comprising a homodimer of heavy chain polypeptides, whereby the antigen is recognized by virtue of one single domain.

Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonAntibodies in Drug